Clinical Trials · NCT01860742

Randomized Phase III of PRRT Versus Interferon

WithdrawnPhase 3Octreotide (Prohibited)
Phase
Phase 3
Recruitment status
Withdrawn
Sponsor
Jules Bordet Institute
Enrollment
0
Start date
Dec 2014
Locations
2 sites, Belgium
Primary endpoint
Progression Free Survival (PFS)
View Octreotide compound reference